focus -WSS

focus

author：leisure time 2025-10-06 19:20:40 - browse：3796

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Pushing for an NIH office for post

Wikipedia

WSS

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

How to bring more disabled researchers into academia

Air quality improving but still lags in Black, Hispanic communities

WuXi out of biotech trade group, U.S. and China relations to blame

Readout Newsletter: Bristol, Sangamo, Gilead, and more

First U.S. drug developed to treat liver disease MASH is approved

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Amylyx ALS drug fails large clinical trial

United colonoscopy coverage change 'may cost lives,' doctors say

Change Healthcare outage fallout shows need for new oversight

Supreme Court strikes down use of affirmative action

How to save health care price transparency rules

Wildfire smoke exposes gaps in outdoor worker protections

Why scientists need input from humanists on sensitive research

hotspot

How many hemophilia patients actually want gene therapy?

President Biden's budget: Here's what you might have missed

RSV shot was 90% effective at preventing hospitalizations in kids

FDA advisers back CAR

How many hemophilia patients actually want gene therapy?

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

hotspot

focus

Wikipedia

Wikipedia